Atherosclerotic Cardiovascular Disease
PCSK9 inhibitors lower VTE risk in patients with elevated Lp(a)
Patients treated with PCSK9 inhibitors had reduced risk for venous thromboembolism, especially if they had elevated lipoprotein(a), according to findings presented at the virtual American College of Cardiology Scientific Session.
FDA approves bempedoic acid/ezetimibe for LDL lowering in ASCVD, HeFH
Esperion Therapeutics announced that a medication combining bempedoic acid and ezetimibe to lower LDL in adults with heterozygous familial hypercholesterolemia or established atherosclerotic CVD has been approved by the FDA.
FDA approves bempedoic acid for LDL lowering in high-risk populations
The FDA has approved bempedoic acid for reducing LDL as an adjunct to diet and maximally tolerated statin therapy in patients with heterozygous familial hypercholesterolemia or established atherosclerotic CVD, according to the agency’s website and an alert from Esperion Therapeutics.
Lower target LDL after stroke prevents 25% of events at 5 years
During the 5 years after a stroke, targeting LDL of less than 70 mg/dL prevented more than one-quarter of major CV events, recurrent cerebral infarction or urgent carotid revascularization and recurrent cerebral infarction or hemorrhage vs. an LDL target of less than approximately 100 mg/dL.
Physical inactivity confers similar ASCVD risk to smoking status
Physical inactivity was associated with an excess risk for atherosclerotic CVD similar to smoking and poor cholesterol levels, according to a research letter published in the European Journal of Preventive Cardiology.
Large waist circumference increases recurrent event risk after MI
Abdominal obesity was common in patients post-MI, and a larger waist circumference in this population was independently linked with recurrent atherosclerotic CVD, especially in men, according to a study published in the European Journal of Preventive Cardiology.
Novel score may predict CV event risk similarly to ASCVD risk score
A novel score to predict 10-year risk for incident CV events using patient-reported information was comparable to the atherosclerotic CVD risk score, according to a study published in the Journal of the American Heart Association.
Differences in dyslipidemia guidelines underscore complexity of CVD prevention
The cornerstone of CV prevention is risk assessment because patients at higher risk for atherosclerotic events typically derive a higher absolute benefit from preventive therapies.
Can green tea prevent atherosclerotic CVD? Read the week’s top stories in cardiology
Green tea may lower risk for ASCVD, mortality in Chinese population
Habitual drinking of tea, particularly green tea, confers a significant reduction in risk for atherosclerotic CVD and all-cause mortality, according to research published in the European Journal of Preventive Cardiology.